Pinnacle Research Group, LLC

Running trials

• Recruiting

  AMAZE 9: A Research Study Investigating How Well Zenagamtide Tablets Help People With Excess Body Weight Lose Weight

  NCT07720271· Phase 3· Source

• Recruiting

  A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity

  NCT07794579· Phase 3· Source

• Recruiting

  Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)

  NCT07684235· Phase 3· Source

• Active, not recruiting

  AMAZE 12: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Maintain Their Weight Loss

  NCT07503210· Phase 3· Source

• Recruiting

  A Study of LY4213663 in Healthy Participants and Participants With Rheumatoid Arthritis

  NCT07258849· Phase 1· Source

• Recruiting

  EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease

  NCT07064473· Phase 3· Source

• Active, not recruiting

  Study of GS-0151 in Participants With Rheumatoid Arthritis

  NCT06902519· Phase 1· Source

• Active, not recruiting

  Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight

  NCT06858839· Phase 3· Source

• Active, not recruiting

  A Study to Investigate Weight Management With Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Adults With Obesity or Overweight

  NCT06643728· Phase 2· Source

• Active, not recruiting

  Two-period Crossover Study to Demonstrate the Comparability of Pharmacokinetics of Subcutaneous Ianalumab Between 2mL Auto-injector/2mL PFS with1mL Pre-filled Syringe in Adult Participants With Autoimmune Disease

  NCT06293365· Phase 2· Source

• Recruiting

  Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).

  NCT06133972· Phase 3· Source

• Active, not recruiting

  Phase 3 Study to Evaluate Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 2)

  NCT05624749· Phase 3· Source

• Active, not recruiting

  Phase 3 Study to Evaluate Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 1)

  NCT05639114· Phase 3· Source

• Active, not recruiting

  A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus

  NCT05531565· Phase 2/3· Source

• Active, not recruiting

  Evaluation of the ctDNA LUNAR Test in an Average Patient Screening Episode

  NCT04136002· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Obesity3 recruiting
• High blood pressure1 recruiting
• Lupus (SLE)1 recruiting
• Rheumatoid arthritis1 recruiting
• Type 2 diabetes1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose Weight

  NCT06066528· Phase 3· Source

• Completed

  A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight

  NCT05929079· Phase 3· Source

• Completed

  A Study of DS-7011a in Patients With Systemic Lupus Erythematosus

  NCT05638802· Phase 1/2· Source

• Completed

  Safety and Efficacy of Bimagrumab and Semaglutide in Adults Who Are Overweight or Obese

  NCT05616013· Phase 2· Source

• Completed

  An Efficacy, Safety, Tolerability and Dose Finding Study of XXB750 in Resistant Hypertension Patients.

  NCT05562934· Phase 2· Source

• Completed

  A Study of LY3457263 Alone and in Combination With Dulaglutide (LY2189265) in Participants With Type 2 Diabetes

  NCT05377333· Phase 1· Source

• Recruiting

  ConsideRAte Study - Splenic Stimulation for RA

  NCT05003310· Source

• Completed

  Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin)

  NCT04392154· Phase 3· Source